Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells

J Immunol. 2011 Aug 15;187(4):1664-73. doi: 10.4049/jimmunol.1100755. Epub 2011 Jul 15.

Abstract

Imiquimod is a TLR7/8 agonist that has anticancer therapeutic efficacy in the treatment of precancerous skin lesions and certain nonmelanoma skin cancers. To test our hypothesis that imiquimod enhances DNA repair as a mechanism for its anticancer activity, the nucleotide excision repair genes were studied in bone marrow-derived cells. Imiquimod enhanced the expression of xeroderma pigmentosum (XP) A and other DNA repair genes (quantitative real-time PCR analysis) and resulted in an increased nuclear localization of the DNA repair enzyme XPA. This was dependent on MyD88, as bone marrow-derived cells from MyD88(-/-) mice did not increase XPA gene expression and did not enhance the survival of MyD88(-/-)-derived bone marrow-derived cells after UV B exposure as was observed in bone marrow-derived cells from MyD88(+/+) mice. Imiquimod also enhanced DNA repair of UV light (UVL)-irradiated gene expression constructs and accelerated the resolution of cyclobutane pyrimidine dimers after UVL exposures in P388 and XS52. Lastly, topical treatment of mouse skin with 5% imiquimod cream prior to UVL irradiation resulted in a decrease in the number of cyclobutane pyridimine dimer-positive APC that were found in local lymph nodes 24 h after UVL irradiation in both wild-type and IL-12 gene-targeted mice. In total, these data support the idea that TLR7 agonists such as imiquimod enhance DNA repair in bone marrow-derived cells. This property is likely to be an important mechanism for its anticancer effects because it protects cutaneous APC from the deleterious effects of UVL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoquinolines / pharmacology*
  • Animals
  • Antineoplastic Agents / pharmacology*
  • Bone Marrow Cells / immunology*
  • Bone Marrow Cells / metabolism
  • Cell Line
  • DNA Damage* / drug effects
  • DNA Damage* / immunology
  • DNA Damage* / radiation effects
  • DNA Repair / drug effects
  • DNA Repair / genetics
  • DNA Repair / immunology
  • DNA Repair / radiation effects
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Expression Regulation, Neoplastic / genetics
  • Gene Expression Regulation, Neoplastic / immunology
  • Gene Expression Regulation, Neoplastic / radiation effects
  • Imiquimod
  • Membrane Glycoproteins / agonists*
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / immunology*
  • Membrane Glycoproteins / metabolism
  • Mice
  • Mice, Knockout
  • Myeloid Differentiation Factor 88 / genetics
  • Myeloid Differentiation Factor 88 / immunology
  • Myeloid Differentiation Factor 88 / metabolism
  • Pyrimidine Dimers / genetics
  • Pyrimidine Dimers / immunology
  • Pyrimidine Dimers / metabolism
  • Signal Transduction* / drug effects
  • Signal Transduction* / immunology
  • Signal Transduction* / radiation effects
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / genetics
  • Skin Neoplasms / immunology*
  • Toll-Like Receptor 7 / agonists*
  • Toll-Like Receptor 7 / genetics
  • Toll-Like Receptor 7 / immunology*
  • Toll-Like Receptor 7 / metabolism
  • Ultraviolet Rays / adverse effects*
  • Xeroderma Pigmentosum Group A Protein / biosynthesis
  • Xeroderma Pigmentosum Group A Protein / genetics
  • Xeroderma Pigmentosum Group A Protein / immunology

Substances

  • Aminoquinolines
  • Antineoplastic Agents
  • Membrane Glycoproteins
  • Myd88 protein, mouse
  • Myeloid Differentiation Factor 88
  • Pyrimidine Dimers
  • Tlr7 protein, mouse
  • Toll-Like Receptor 7
  • Xeroderma Pigmentosum Group A Protein
  • Xpa protein, mouse
  • Imiquimod